Lenmeldy is a one-time, individualized single-dose infusion made from a patient’s own hematopoietic stem cells, which have been genetically modified to include functional copies of the ARSA gene that codes for the arylsulfatase A enzyme. It is indicated for presymptomatic late infantile, presymptomatic early juvenile, or early symptomatic early juvenile MLD.
The priority-review orphan drug approval was based on data from 37 children who received Lenmeldy. Compared with untreated children, Lenmeldy significantly reduced the risk for severe motor impairment or death.
All children with presymptomatic late infantile MLD treated with Lenmeldy were alive at 6 years of age versus only 58 percent of untreated children. Seven in 10 treated children (71 percent) were able to walk without assistance at 5 years of age, and 85 percent had normal language and performance IQ scores.
Children with presymptomatic early juvenile and early symptomatic early juvenile MLD showed slowing of motor and/or cognitive disease with Lenmeldy.
“MLD is a devastating disease that profoundly affects the quality of life of patients and their families. Advancements in treatment options offer hope for improved outcomes and the potential to positively influence the trajectory of disease progression,” Nicole Verdun, M.D., director of the Office of Therapeutic Products at the FDA, said in a statement.
“This approval represents important progress in the advancement and availability of effective treatments, including gene therapies, for rare diseases.”
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Promising Early Results for Gene Therapy DB-OTO in Treating Genetic Deafness
Regeneron Pharmaceuticals, Inc. recently shared encouraging early results from the ongoing Phase I/II CHORD trial of DB-OTO, a gene therapy aimed at treating genetic deafness caused by variants of the otoferlin gene. The data was presented at the American Society of...
Groundbreaking CoCas9 Enzyme Unveiled: A Compact and Efficient CRISPR Tool for Genetic Therapy
Introduction: A revolutionary stride has been made in the field of genetic engineering, as researchers from the University of Trento introduce a novel CRISPR enzyme, CoCas9, which promises to enhance the delivery and efficacy of in vivo gene therapy using...
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1
Avidity initiating global Phase 3 HARBOR™ study for delpacibart etedesiran this quarter Delpacibart etedesiran data from MARINA-OLE™ showed reversal of disease progression in multiple functional measures in DM1 compared to END-DM1 natural history data SAN DIEGO, May...
NANITE AWARDED $1.8M TO DEVELOP AI-DRIVEN GENE THERAPY FOR HIV
Nanite Receives Funding to Employ SAYERTM Platform to Develop Non-Viral Delivery Vehicles to Express Neutralizing Antibodies In Vivo from the Bill & Melinda Gates Foundation BOSTON, May 8, 2024 /PRNewswire/ -- Nanite, Inc. today announced a $1.8M grant from the...
Related Services